MY159500A - Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response - Google Patents

Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Info

Publication number
MY159500A
MY159500A MYPI2011005631A MYPI2011005631A MY159500A MY 159500 A MY159500 A MY 159500A MY PI2011005631 A MYPI2011005631 A MY PI2011005631A MY PI2011005631 A MYPI2011005631 A MY PI2011005631A MY 159500 A MY159500 A MY 159500A
Authority
MY
Malaysia
Prior art keywords
herpes simplex
simplex virus
eliciting
compositions
methods
Prior art date
Application number
MYPI2011005631A
Other languages
English (en)
Inventor
Deborah Long
Jessica Flechtner
Mojca Skoberne
R Siber George
Original Assignee
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc filed Critical Genocea Biosciences Inc
Publication of MY159500A publication Critical patent/MY159500A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MYPI2011005631A 2009-05-22 2010-05-24 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response MY159500A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18078409P 2009-05-22 2009-05-22
US23562809P 2009-08-20 2009-08-20
US24062609P 2009-09-08 2009-09-08
US24058709P 2009-09-08 2009-09-08
US30591810P 2010-02-18 2010-02-18

Publications (1)

Publication Number Publication Date
MY159500A true MY159500A (en) 2017-01-13

Family

ID=43126545

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011005631A MY159500A (en) 2009-05-22 2010-05-24 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Country Status (17)

Country Link
US (3) US8617564B2 (enExample)
EP (3) EP2432504B1 (enExample)
JP (2) JP5771605B2 (enExample)
KR (1) KR101746872B1 (enExample)
CN (2) CN106924728B (enExample)
AU (1) AU2010249330B2 (enExample)
BR (1) BRPI1012811A2 (enExample)
CA (1) CA2797937C (enExample)
ES (1) ES2732815T3 (enExample)
IL (1) IL216508A (enExample)
MX (1) MX2011012347A (enExample)
MY (1) MY159500A (enExample)
NZ (1) NZ597182A (enExample)
RU (1) RU2585961C9 (enExample)
SG (1) SG176207A1 (enExample)
WO (2) WO2010135749A1 (enExample)
ZA (1) ZA201109444B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
JP6055776B2 (ja) * 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012139099A2 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus vaccine
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
US20140093537A1 (en) * 2012-09-30 2014-04-03 Nanobio Corporation Immunogenic compositions comprising nanoemulsion and methods of administering the same
CN103074337B (zh) * 2012-12-04 2014-07-09 昆明寰基生物芯片产业有限公司 一段单纯疱疹病毒dna序列及应用
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
CN106456805B (zh) 2014-03-03 2020-01-10 阿尔伯特爱因斯坦医学院公司 重组单纯疱疹病毒2(hsv-2)疫苗载体
PT3411388T (pt) 2016-02-01 2021-12-20 Simplexia Ab Glicoproteína g truncada do vírus herpes simplex 2
ES2796488T3 (es) * 2016-04-08 2020-11-27 Krystal Biotech Inc Composiciones para el uso en métodos para el tratamiento de heridas, trastornos y enfermedades de la piel
EP3519427A4 (en) * 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
KR101962683B1 (ko) * 2016-09-28 2019-03-27 주식회사 에스엘백시젠 Hsv-2 감염 예방 및 치료용 dna 백신
WO2018200613A1 (en) * 2017-04-26 2018-11-01 Merck Sharp & Dohme Corp. Hsv antigenic peptides and hsv protein vaccines
CA3073161A1 (en) * 2017-08-17 2019-02-21 The Trustees Of The University Of Pennsylvania Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
US11213582B2 (en) * 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
EP3856914A1 (en) 2018-09-26 2021-08-04 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
CN113454105A (zh) 2019-02-08 2021-09-28 克里斯托生物技术股份有限公司 用于递送cftr多肽的组合物和方法
KR20210141554A (ko) 2019-03-21 2021-11-23 코디악 바이오사이언시즈, 인크. 세포외 소포 접합체 및 이의 용도
WO2020191361A2 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicles for vaccine delivery
CN109943592B (zh) * 2019-04-29 2020-11-17 华中农业大学 含猪伪狂犬病病毒gD蛋白基因的重组杆状病毒转移载体、重组杆状病毒及制备方法和应用
CN110804088A (zh) * 2019-11-18 2020-02-18 维塔恩(广州)医药有限公司 巨细胞病毒相关抗原短肽及其应用
CN110845583A (zh) * 2019-11-18 2020-02-28 维塔恩(广州)医药有限公司 水痘带状疱疹病毒相关抗原短肽及其应用
CN110724181A (zh) * 2019-11-18 2020-01-24 维塔恩(广州)医药有限公司 单纯疱疹病毒相关抗原短肽及其应用
CN110746497A (zh) * 2019-11-18 2020-02-04 维塔恩(广州)医药有限公司 肺炎衣原体相关抗原短肽及其应用
IL307350A (en) 2021-04-02 2023-11-01 Krystal Biotech Inc Viral vectors for cancer treatment
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
WO1990013652A1 (en) 1989-05-12 1990-11-15 Triton Diagnostics, Inc. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
CA2088600C (en) 1990-08-02 1999-11-16 Rae L. Burke Herpes simplex virus vp16 vaccines
DK31991D0 (da) 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
EP0708833A1 (en) 1993-06-08 1996-05-01 Abbott Laboratories Herpes simplex virus type-2 protease
JPH09503385A (ja) 1993-08-20 1997-04-08 スミスクライン・ビーチャム・コーポレイション Ｈｓｖ−２ｕｌ２６遺伝子、カプシド蛋白、イムノアッセイおよびプロテアーゼ阻害剤
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US7094767B2 (en) 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US5807557A (en) 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
US6156319A (en) * 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6197497B1 (en) 1995-04-21 2001-03-06 University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
JP2002514056A (ja) 1996-10-23 2002-05-14 アメリカン・ホーム・プロダクツ・コーポレーション ワクチン
CN1324139C (zh) * 1996-10-23 2007-07-04 惠氏 疫苗
CA2270282A1 (en) 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
US6218103B1 (en) * 1997-04-16 2001-04-17 Arch Development Corporation Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis
CA2291010A1 (en) 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6054131A (en) 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
TR200002608T2 (tr) 1998-03-09 2000-11-21 Smithkline Beecham Biologicals S.A Kombine aşı kompozisyonları
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
CN1348463A (zh) 1998-08-07 2002-05-08 华盛顿大学 免疫学单纯疱疹病毒抗原及其使用方法
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
BR0011732B1 (pt) 1999-06-10 2014-02-04 Vacinas de dna para animais de companhia e de esporte
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
JP2003512305A (ja) 1999-09-30 2003-04-02 ユニバーシティ オブ ワシントン 免疫学的に重要な単純疱疹ウイルス抗原
US7196066B1 (en) * 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
EP1238086B1 (en) * 1999-12-17 2006-03-08 Wyeth Holdings Corporation Vaccine for enhancing immune responses to herpes simplex virus
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US6537555B2 (en) 2000-06-29 2003-03-25 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030165819A1 (en) 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
DE60131975T2 (de) 2000-07-27 2008-12-18 The Trustees Of The University Of Pennsylvania Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
US20040220076A1 (en) 2000-11-16 2004-11-04 Laure Aurelian Prevention of recurrent viral disease
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
EP2545937A1 (en) 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
CA2454750C (en) 2001-07-31 2012-09-18 David M. Koelle Immunologically significant herpes simplex virus antigens and methods for using same
WO2003020108A2 (en) 2001-09-04 2003-03-13 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20080299140A1 (en) 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
US20030219448A1 (en) * 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
DE60324678D1 (de) 2002-07-18 2008-12-24 Univ Washington N t-lymphozyten und damit identifizierte hsv-antigene
US7267940B2 (en) 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20120027841A1 (en) 2004-01-07 2012-02-02 Biomedical Research Models, Inc. Novel mucosal vaccination approach for herpes simplex virus type-2
US20070196389A1 (en) 2005-11-18 2007-08-23 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
WO2007106404A2 (en) 2006-03-10 2007-09-20 The Regents Of The University Of California Vaccine for viruses that cause persistent or latent infections
US7628993B2 (en) 2006-07-20 2009-12-08 Vical Incorporated Compositions and methods for vaccinating against HSV-2
US20090246220A1 (en) 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
EP2059255A4 (en) 2006-09-08 2011-08-31 Univ Pennsylvania HSV-1 AND HSV-2 VACCINES AND METHOD FOR THEIR USE
EP2087128A4 (en) 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US9284355B2 (en) * 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US7785605B2 (en) 2007-07-05 2010-08-31 University Of Kansas Herpes simplex virus mutant ICP0 protein
AU2008274887B2 (en) 2007-07-06 2013-10-31 The University Of Sydney Epitopes of herpes simplex virus
EP2293814A4 (en) * 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION AGENTS
SE532551C2 (sv) 2008-06-30 2010-02-16 Senseair Ab Ett för spektralanalys anpassat arrangemang
US8313894B2 (en) 2008-07-01 2012-11-20 Genocea Biosciences, Inc. Antigen screening system
CA2781805A1 (en) 2008-12-17 2010-07-08 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
CA2754592A1 (en) 2009-03-09 2010-09-16 William Henry Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
US9089537B2 (en) 2010-02-26 2015-07-28 The Trustees Of The University Of Pennslyvania Subunit vaccines for herpes viruses and methods of use
CA2849391A1 (en) 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
EP3519427A4 (en) 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES

Also Published As

Publication number Publication date
US20100330112A1 (en) 2010-12-30
CA2797937C (en) 2020-01-14
EP3756684A1 (en) 2020-12-30
US10653771B2 (en) 2020-05-19
WO2010135747A1 (en) 2010-11-25
CN102458463A (zh) 2012-05-16
US20180369365A1 (en) 2018-12-27
EP2432504A1 (en) 2012-03-28
US20140227307A1 (en) 2014-08-14
SG176207A1 (en) 2011-12-29
CN106924728A (zh) 2017-07-07
US9895436B2 (en) 2018-02-20
WO2010135749A1 (en) 2010-11-25
BRPI1012811A2 (pt) 2016-03-29
JP5771605B2 (ja) 2015-09-02
CN106924728B (zh) 2021-02-05
CN102458463B (zh) 2017-01-18
EP3590533A1 (en) 2020-01-08
IL216508A0 (en) 2012-02-29
CA2797937A1 (en) 2010-11-25
IL216508A (en) 2016-08-31
JP6096839B2 (ja) 2017-03-15
RU2011147153A (ru) 2013-06-27
EP2432504B1 (en) 2019-05-01
RU2585961C2 (ru) 2016-06-10
NZ597182A (en) 2014-07-25
KR101746872B1 (ko) 2017-06-14
US8617564B2 (en) 2013-12-31
ES2732815T3 (es) 2019-11-26
MX2011012347A (es) 2012-02-21
AU2010249330A1 (en) 2012-01-19
JP2012527486A (ja) 2012-11-08
ZA201109444B (en) 2016-09-28
JP2015178529A (ja) 2015-10-08
RU2585961C9 (ru) 2016-12-27
WO2010135749A9 (en) 2011-07-21
AU2010249330B2 (en) 2015-11-05
EP2432504A4 (en) 2013-07-31
KR20120087805A (ko) 2012-08-07

Similar Documents

Publication Publication Date Title
MX2011012347A (es) Vacunas contra virus del herpes simple tipo 2: composiciones y metodos para obtener una respuesta inmunitaria.
WO2012074881A3 (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
TW200806316A (en) Yeast-based vaccine for inducing an immune response
WO2009128950A3 (en) Deletion mutants of flagellin and methods of use
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
NZ601345A (en) Combination adjuvant formulation
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
WO2015142671A3 (en) Influenza virus vectors and uses therefor
GB201009273D0 (en) Novel vaccine
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
PL1951299T3 (pl) Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
MY202024A (en) Novel mucosal adjuvants and delivery systems
WO2011079073A3 (en) Herpes simplex virus vaccines
WO2009092113A3 (en) Methods and compositions for the delivery of vaccines to disrupted epithelium
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
MX2016001695A (es) Composiciones inmunogenas de combinacion.
HK1210475A1 (en) Herpes simplex virus vaccine
UA100710C2 (ru) Композиция для индукции иммунной реакции против вируса bluetongue (btv) у животного
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
UA101385C2 (ru) Иммунологическая композиция, которая в качестве адъюванты содержит сульфолипо-циклодекстрин (sl-cd) и сапонин
WO2011100408A3 (en) Serologic correlates of protection against bacillis anthracis infection
WO2007120860A3 (en) Nanoemulsion vaccines